DIA DiaSorin S.p.A.

87.11USD79.42 EUR · BIT-2.22%Mkt Cap: 4.29B USDP/E: 29.20

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiag…

Institutional holders11 on file

Key Statistics

Company
Market Cap4.29B USD
Enterprise Value5.05B USD
Revenue (TTM)1.32B USD
Gross Profit848.35M USD
Net Income (TTM)170.69M USD
Revenue/Share26.70 USD
Last Price87.11 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees3.2K
CountryIT
SectorHealthcare
IndustryDiagnostics & Research
ISINIT0003492391
Valuation
P/E (Trailing)29.20
P/E (Forward)18.25
PEG1.73
EV/EBITDA12.85
EV/Revenue3.82
P/S3.25
P/B2.68
EPS (TTM)2.98 USD
EPS (Forward)4.77 USD
52W Range
57.4181% of range94.13
52W High94.13 USD
52W Low57.41 USD
Profitability
Gross Margin64.72%
Oper. Margin22.34%
EBITDA Margin29.73%
Profit Margin13.02%
ROE9.82%
ROA5.42%
ROIC8.85%
ROCE11.39%
Growth
Revenue Growth10.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF375.94M USD
CapEx (TTM)151.01M USD
FCF Margin—
FCF Yield—
Net Debt738.59M USD
Net Debt/EBITDA1.88
Net Debt/FCF—
Balance Sheet
Debt/Equity0.50
Current Ratio—
Quick Ratio—
Book Value/Sh32.50 USD
Cash/Share2.40 USD
Dividends
Fwd Div Rate1.43 USD
Trail. Div Rate0.00 USD
Div. Yield1.59%
5Y Avg Yield1.12%
Payout Ratio47.79%
Ex-Div DateMay 18, 2026
Pay Date—
Analyst Consensus
Rating2.8 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)87.34 USD
Upside (mean)+0.3%
Target Range60.32 USD – 115.16 USD
60.32+0.3% to mean115.16
# Analysts14
Ownership
Shares Out.49.27M
Float14.88M
Insiders57.56%
Institutions14.28%
Technical
SMA 5086.34 (+0.9%)
SMA 20077.39 (+12.6%)
Beta0.66
S&P 52W Chg12.00%
Avg Vol (30d)139.25K
Avg Vol (10d)156.86K
Technical Indicators
RSI (14)45.4
MACD0.9107
MACD Signal1.2816
MACD Hist.-0.3709
BB Upper92.91 USD
BB Middle89.54 USD
BB Lower86.17 USD
BB Width7.53%
ATR (14)2.202 USD
Vol Ratio (20d)1.00x

About DiaSorin (BIT: DIA)

›

DiaSorin (BIT: DIA) is listed on Borsa Italiana, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 3,212 employees.

The shares were at 79.42 EUR on 19 November 2026, up 34.8% over 52 weeks. Its 52-week range is 52.34 EUR to 85.82 EUR: the price is 7.5% below the high and 51.7% above the low.

At a market capitalisation of 3.91B EUR, it trades at 29.2 times trailing earnings and 18.2 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 18% for DIA. It pays a dividend yielding 1.59% (it pays out 48% of its earnings), against a median of 0.73% among the dividend payers in that peer group.

DiaSorin reports return on equity of 9.8%, an operating margin of 22.3% and revenue up 10.0% year over year.

Its debt exceeds its cash by 673.40M EUR, a debt-to-equity ratio of 0.50. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Hold; their mean price target of 79.63 EUR is 0.3% above the current price. The next earnings report is expected on 26 March 2027.